Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells

Abstract

The technology described has proven to be more reproducible, efficient and rapid than previously reported techniques, and can be adopted at low overall costs by any cell biology laboratory for the development of fully human mAbs for immunotherapeutic uses.